HIV-1 targeting of IFN regulatory factors

Future Virology

Volumn 6, Issue 12, 2011, Pages 1397-1405

  Remoli, Anna Lisa ^a   Marsili, Giulia ^a   Sgarbanti, Marco ^a   Perrotti, Edvige ^a   Fragale, Alessandra ^a   Orsatti, Roberto ^a   Battistini, Angela ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

gene expression; HIV 1; IFN; IFN regulatory factor; immune evasion; innate immunity; Tat; viral replication

Indexed keywords

INTERFERON; INTERFERON REGULATORY FACTOR;

ARTICLE; CELL FUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE EVASION; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; VIRUS REPLICATION;

EID: 82455186406     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.125     Document Type: Article

References (62)

1. Cullen BR. Regulation of HIV-1 gene expression. FASEB J. 5, 2361-2368 (1991).
2. Van Lint C, Ghysdael J, Paras Jr P, Burnyand A, Verdin E. A transcriptional regulatory element is associated with a nuclease-hypersensitive site in the pol gene of human immunodeficiency virus type. J. Virol. 68, 2632-2648 (1994).
3. Jones KA, Peterlin BM. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63, 717-743 (1994).
4. Gaynor R. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS 6, 347-363 (1992).
5. Wu Y, Marsh JW. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 293, 1503-1506 (2001).
6. Jeang KT, Gatignol A. Comparison of regulatory features among primate lentiviruses. Curr. Top. Microbiol. Immunol. 188, 123-144 (1994).
7. Chang HK, Gallo RC, Ensoli B. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein. J. Biomed. Sci. 2, 189-202 (1995).
8. Romani B, Engelbrecht S, Glashoff RH. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J. Gen. Virol. 91(Pt 1), 1-12 (2010).
9. Harrich D, McMillan N, Munoz L, Apolloni A, Meredith L. Will diverse Tat interactions lead to novel antiretroviral drug targets? Curr. Drug Targets 7(12), 1595-1606 (2006).
10. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19, 623-655 (2001).
11. Battistini A. Interferon regulatory factors in hematopoietic cell differentiation and immune regulation. J. Interferon Cytokine Res. 29(12), 765-780 (2009).
12. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26, 535-584 (2008).
13. el Kharroubi A, Verdin E. Protein-DNA interactions within DNase I-hypersensitive sites located downstreamof the HIV-1 promoter. J. Biol. Chem. 269, 19916-19924 (1994).
14. Van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E. Transcription factor binding sites downstreamof the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J. Virol. 71, 6113-6127 (1997).
15. Sgarbanti M, Borsetti A, Moscufo N et al. Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J. Exp. Med. 195, 1359-1370 (2002).
16. Harada H, Fujita T, Miyamoto M et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58(4), 729-739 (1989).
17. Coccia EM, Del Russo N, Stellacci E et al. Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2. Oncogene 18(12), 2129-2137 (1999).
18. Sgarbanti M, Remoli AL, Marsili G et al. IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer. J. Virol. 82(7), 3632-3641 (2008).
19. Bossis G, Salinas S, Cartier C, Devaux C, Briant L. NF-kappaB activation upon interaction of HIV-1 envelope glycoproteins with cell surface CD4 involves IkappaB kinases. FEBS Lett. 516, 257-264 (2002).
20. Palmer S, Josefsson L, Coffin JM. HIV reservoirs and the possibility of a cure for HIV infection. J. Intern. Med. doi:10.1111/j.1365-2796.2011.02457.x (2011) (Epub ahead of print).
21. Nelson N, Kanno Y, Hong C. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J. Immunol. 156(10), 3711-3720 (1996).
22. Munier S, Delcroix-Genête D, Carthagéna L, Gumez A, Hazan U. Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency. Retrovirology 2, 73 (2005).
23. Harman AN, Lai J, Turville S, et al. HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood 118(2), 298-308 (2011).
24. Huigen MC, Kamp W, Nottet HS. Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection. Eur. J. Clin. Invest. 34, 57-66 (2004).
25. Ensoli B, Buonaguro L, Barillari G et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67, 277-287 (1993).
26. Brady J, Kashanchi F. Tat gets the "green" light on transcription initiation. Retrovirology 2, 69 (2005).
27. Giacca M. The HIV-1 Tat protein: a ultifaceted target for novel therapeutic opportunities. Curr. Drug Targets Immune Endocr. Metabol. Disord. 4(4), 277-285 (2004).
28. Wang IM, Blanco JC, Tsai MJ, Ozato K. Interferon regulatory factors and TFIIB cooperatively regulate interferon-responsive promoter activity in vivo and in vitro. Mol. Cell. Biol. 16, 6313-6324 (1996).
29. Merika M, Williams AJ, Chen G, Collins T, Thanos D. Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of transcription. Mol. Cell 1, 277-287 (1998).
30. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Ann. Rev. Immunol. 17, 739-779 (1999).
31. Ploegh HL. Viral strategies of immune evasion. Science 280, 248 (1998).
32. Gavioli R, Gallerani E, Fortini C et al. HIV- 1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J. Immunol. 173, 3838-3843 (2004).
33. Remoli AL, Marsili G, Perrotti E et al. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem. J. 396(2), 371-380 (2006).
34. Cafaro A, Titti F, Fracasso C et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).Vaccine 19, 2862-2877 (2001).
35. Castaldello A, Sgarbanti M, Marsili G et al. Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination. J. Cell. Physiol. 224(3), 702-709 (2010).
36. Lohoff M, Ferrick D, Mittrucker HW. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 6(6), 681-689 (1997).
37. Honda K, Taniguchi T. IRFs: master regulators of signaling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6, 644-658 (2006).
38. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8, 55-67 (2010).
39. Douville RN, Hiscott J. The interface between the innate interferon response and expression of host retroviral restriction factors. Cytokine 52, 108-115 (2010).
40. Grandvaux N, tenOever BR, Servant MJ, Hiscott J. The interferon antiviral response. fromviaral invasion to evasion. Curr. Opin. Infect. Dis. 15, 259-267 (2002).
41. Kawai T, Akira S. Innate immune recognition of viral infection. Nat. Immunol. 7(2), 131-137 (2006).
42. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303(5663), 1526-1529 (2004).
43. Beignon AS, McKenna K, Skoberne M et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 115(11), 3265-3275 (2005).
44. Meier A, Alter G, FrahmN et al. MyD88- dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J. Virol. 81(15), 8180-8191 (2007).
45. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M Jr. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J. Virol. 83(20), 10395-10405 (2009).
46. Solis M, Nakhaei P, Jalalirad M. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J. Virol. 85(3), 1224-1236 (2011).
47. Lepelley A, Louis S, Sourisseau M et al. Innate sensing of HIV-infected cells. PLoS Pathog. 7(2), E1001284 (2011).
48. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 467(7312), 214-217 (2010).
49. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TB. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat. Immunol. 11(5), 419-426 (2010).
50. Okumura A, Alce T, Lubyova B, Ezelle H, Strebel K, Pitha PM. HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 373, 85-97 (2008).
51. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 11(11), 1005-1013 (2010).
52. Li Q, Estes JD, Schlievert PM. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458(7241), 1034-1038 (2009).
53. Herbeuval JP, Nilsson J, Boasso A. Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc. Natl Acad. Sci USA 103(18), 7000-7005 (2006).
54. Lehmann C, Harper JM, Taubert D. Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 48(5), 522-530 (2008).
55. O'Brien M, Manches O, Lubong Sabado R et al. Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-a-producing and partially atured phenotype. J. Clin. Invest. 121, 1088-1101 (2011).
56. Chang J, Lindsay RJ, Smita K, Lifson JD, Carrington M, Altfeld M. Polymorphisms in IRF7 reduce IFNalpha responses of pDCs to HIV-1. AIDS 25(5), 715-717 (2011).
57. Mandl JN, Barry AP, Vanderford TH et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14, 1077-1087 (2008).
58. Chang JJ, Altfeld M. TLR-mediated immune activation in HIV. Blood 113, 269-270 (2009).
59. Baenziger S, Heikenwalder M, Johansen P et al. Triggering TLR7 in mice induces immune activation and lymphoid systemdisruption, resembling HIV-mediated pathology. Blood 113(2), 377-388 (2009).
60. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12(12), 1365-1371 (2006).
61. Mogensen TH, Melchjorsen J, Larsen CS, Paludan SR. Innate immune recognition and activation during HIV infection. Retrovirology 7, 54 (2010).
62. Su RC, Sivro A, Kimani J, Jaoko W, Plummer FA, Ball TB. Epigenetic control of IRF1 responses in HIV-exposed seronegative versus HIV-susceptible individuals. Blood 117(9), 2649-2657 (2011).